Sign in
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
Episode 12: RPE Stem Cells for Dry AMD with Dr. Mark Humayun
Keyvan Koushan, MD, FRCSC
Member Podcasts
2018
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD
Annual Meeting Talks
Category: AMD-Non-Neovascular